S

Sosei Group Corp
TSE:4565

Watchlist Manager
Sosei Group Corp
TSE:4565
Watchlist
Price: 1 022 JPY -1.16% Market Closed
Market Cap: 91.9B JPY
Have any thoughts about
Sosei Group Corp?
Write Note

Sosei Group Corp
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sosei Group Corp
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
S
Sosei Group Corp
TSE:4565
Operating Expenses
-ÂĄ26.4B
CAGR 3-Years
-43%
CAGR 5-Years
-24%
CAGR 10-Years
-37%
Takeda Pharmaceutical Co Ltd
TSE:4502
Operating Expenses
-ÂĄ2.5T
CAGR 3-Years
-14%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Daiichi Sankyo Co Ltd
TSE:4568
Operating Expenses
-ÂĄ1T
CAGR 3-Years
-21%
CAGR 5-Years
-17%
CAGR 10-Years
-9%
Otsuka Holdings Co Ltd
TSE:4578
Operating Expenses
-ÂĄ1.2T
CAGR 3-Years
-15%
CAGR 5-Years
-9%
CAGR 10-Years
-3%
Chugai Pharmaceutical Co Ltd
TSE:4519
Operating Expenses
-ÂĄ265B
CAGR 3-Years
-5%
CAGR 5-Years
-5%
CAGR 10-Years
-5%
Astellas Pharma Inc
TSE:4503
Operating Expenses
-ÂĄ1.3T
CAGR 3-Years
-15%
CAGR 5-Years
-12%
CAGR 10-Years
-7%
No Stocks Found

Sosei Group Corp
Glance View

Market Cap
91.9B JPY
Industry
Pharmaceuticals

Sosei Group Corp. engages in the discovery, design, and development of medicines targeting G protein-coupled receptors (GPCRs). The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 198 full-time employees. The company went IPO on 2004-07-29. The pharmaceutical business is engaged in the research, development and sales of medicines, the management of regenerative medical funds, the investment in bio venture companies related to regenerative medicine, the overseas development by licensing, the promotion of commercialization, the structural analysis of GPCR, the initial lead compound creation, the candidate search by proprietary StaR technology, as well as structural base of new drugs using GPCR related basic technology drug discovery, screening, promotion of antibody drug research and development.

Intrinsic Value
1 330.98 JPY
Undervaluation 23%
Intrinsic Value
Price
S

See Also

What is Sosei Group Corp's Operating Expenses?
Operating Expenses
-26.4B JPY

Based on the financial report for Sep 30, 2024, Sosei Group Corp's Operating Expenses amounts to -26.4B JPY.

What is Sosei Group Corp's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-37%

Over the last year, the Operating Expenses growth was -78%. The average annual Operating Expenses growth rates for Sosei Group Corp have been -43% over the past three years , -24% over the past five years , and -37% over the past ten years .

Back to Top